CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In the mouse model the combination of TKI showed toxicity toward healthy HSC, but to a lesser extent than toward CD34+ CML cells, which suggested that combinatorial TKI therapy is advantageous over TKI monotherapy.